Objective HIV/AIDS is responsible for widespread clinical manifestations involving the head, and neck. The prevalence and nature of vestibular involvement is still largely unknown. This study, aimed to describe and compare the occurrence and nature of vestibular involvement among a group of, adults infected with HIV compared to a control group. It also aimed to compare the vestibular function, of symptomatic and asymptomatic HIV positive adults who receive antiretroviral (ARV) therapies to, subjects not receiving ARV.
Introduction
The human immunodeficiency virus (HIV) and acquired immunodeficiency syndrome duration (AIDS) is a world-wide pandemic affecting the lives of millions of people. Despite the number of new infections and AIDS-related deaths decreasing between 2001 and 2009, the overall number of individuals living with the disease is still very high [1] .
Increased life expectancy and of survival of those living with HIV/AIDS may, among other factors such as public health education and awareness programmes, be attributed to antiretroviral (ARV) therapy and improvements in access to health care services. The reduction in morbidity and mortality is changing HIV/AIDS from a life-threatening disease to a chronic illness with an increasing emphasis on quality of life issues [2] .
After HIV binds with and penetrates into the CD4+ cell, it compromises the body's immune response gradually and predisposes it to opportunistic infections [3, 4] . Diseases involving the head and neck area are often the first signs of an immune compromised body and may occur in as many as 40% to 90% of individuals with HIV/AIDS [5] [6] [7] [8] [9] . Common HIV/AIDSassociated head and neck pathologies include manifestations in the central nervous system (CNS), the naso-, oro-and laryngopharynx and in the inner ear, that may result in hearing loss and/or vestibular disorders [10] [11] [12] .
There is growing evidence that HIV/AIDS could either directly or indirectly, through opportunistic infections or ototoxic medication, have an adverse effect on the delicate structures of the ear, causing a conductive, mixed or sensorineural hearing loss [13] [14] [15] [16] [17] [18] [19] .
Auditory dysfunction has been reported to occur in between 20% to 75% of adults with HIV/AIDS [20] [21] [22] [23] . The auditory and vestibular system is situated in the temporal bone and constitutes part of the same membranous labyrinth. It is not surprising that with auditory symptoms, which often accompany HIV/AIDS, vestibular dysfunction and associated symptoms may also occur. Vestibular symptoms may include dizziness, vertigo, disequilibrium and/or nausea and vomiting.
However, only a limited number of studies have investigated vestibular dysfunction and pathology related to HIV/AIDS, despite the shared anatomy and physiology of the auditory system [2] . Teggi and colleagues [18] suggested that vestibular symptoms are often masked by other more serious and life-threatening illnesses and disorders associated with HIV/AIDS. As a result, the nature of vestibular symptoms and the potential for manifestations of vestibular pathology resulting from HIV/AIDS have been largely neglected.
The most recent and extensive reports were group studies of adults [17, 18, 24, 25] and children [16] infected with HIV who underwent auditory and vestibular assessments. The findings demonstrated vestibular dysfunction to be more frequent among subjects with HIV than those without HIV. Signs of both peripheral (involving the vestibular end-organs and eighth cranial nerve) and central (vestibular nuclei in the brainstem, cerebellum and oculomotor, vestibulospinal and proprioceptive pathways) vestibular dysfunction have been reported [16] [17] [18] 24, 25] . Vestibular dysfunction occurred across all categories of the disease with a higher prevalence in more advanced categories, particularly regarding central vestibular involvement [17, 18, 26] . These studies employed various tests of 
Materials and methods

Ethical clearance and informed consent
The institutional review boards of the University of Pretoria and the tertiary referral hospital where subjects were registered, reviewed and approved the study before any data collection commenced. Subjects provided written informed consent for the researcher to access their medical records, to have access to their HIV status, to document the CD4+ cell count and the use of ARV therapies.
Study design
A cross-sectional comparative research design was employed. A convenience sampling method was used to recruit subjects. Table 1 summarizes the description of participating subjects. A total of 91 subjects participated, comprising 53 HIV positive and 38 HIV negative adults. There were no statistically significant differences in mean ages between the groups (p=0.26; t-test) and therefore there was not a difference in age groups. Since age only affects the vestibular system after 55 to 65 years [27] , the age of the subjects were below 50 in order to minimize the likelihood of age affecting the results. Age distribution was the same across the two study groups (Mann-Whitney U test). In addition, gender distribution was similar between and within the groups. HIV positive subjects were evenly distributed between the three Centre for Disease Control and Prevention (CDC) classification categories (p>0.05; one-way ANOVA). Fifteen subjects were in category 1 (eight male, seven female), 20 subjects were in category 2 (eight male, 12 female) and 18 subjects were in category 3 (eight male, 10 female). Table 1 furthermore shows the ARV therapy regimes for the subjects with HIV. There were 42 subjects with HIV who used ARV therapies and 11 subjects with HIV who did not use ARV therapies at the time of entry in the study. Table 2 summarizes the data collection protocol, its sequence and purpose. Prior to data collection, subjects were provided with a letter requesting of informed consent that also explained the procedures for the auditory and vestibular assessments as well as a written list of pre-test instructions. The list of pre-test instructions explained that subjects were not permitted to take medication that may suppress vestibular symptoms, or agents such as alcohol and/or sedatives that may suppress peripheral and/or central vestibular function and influence the results and their interpretation. The procedures for the first two points in Table 2 were a medical record review to document subjects' CD4+ cell counts at the time of participation in the study, use of antiretroviral agents and a structured interview. We used the questionnaire from Goebel [29] to probe for any subjective perception of vestibular symptoms. The remainder of the test procedures as indicated in Table 2 were performed in a single session lasting approximately two hours. 
Subjects
Procedures
Structured interview
Subjective perception of any vestibular symptoms (questionnaire from Goebel [29] ).
Otologic and audiologic examination
Otoscopy, tympanometry, pure tone audiometry 
Evoked potentials
Caloric irrigation* Bithermal caloric irrigation, directional preponderance
Note: *Video nystagmography (VNG) with binocular infrared goggles were used to observe and record eye movements and nystagmus
Otologic and audiological examination
Outer ear functioning was assessed through an otoscopic examination. A physician managed the ear canals of subjects with impacted cerumen prior to the vestibular evaluation. Tympanometry was performed using a diagnostic Y-226 Hz probe tone (GSI Tympstar, Grason-Stadler, Eden Prairie, MN, USA). The following criteria [30] were used for normal adult admittance profiling: ear canal volume (0.8 to 2.0 ml), compliance (0.3 to 1.8 ml) and middle ear pressure (-100 daPa to +50 daPa). Pure tone audiometry (air and bone conduction) was performed to determine the presence of air-bone gaps. VEMP data was not analysed if air-bone gaps were greater than 10dB.
VEMP testing
cVEMPs were measured with the non-inverting electrode placed on the medial portion of the sternocleidomastoid muscle (SCM), the inverting electrode on Fpz and ground on Fz (Biologic Navigator Pro, Natus Medical Incorporated, San Carlos, CA, USA). Skin impedance was less than 5kΩ. Wester [31] Maes and colleagues [34] and was proved to provide reliable VEMP amplitudes. All measurements, both present and absent responses, were repeated to test for wave repeatability. The first positive peak on the waveforms was marked P1, while the first negative deflection was marked N1. The following VEMP asymmetry ratio formula was and N1), (ii) two standard deviations above the mean of the HIV negative group were used to calculate the upper limits for P1 and N1 latencies (17.0ms and 26.3ms respectively).
Latencies above these upper limits were regarded as present yet delayed, and considered abnormal and (iii) the presence of an amplitude asymmetry ratio of ≥40% was considered abnormal, since it indicates side-to-side amplitude differences [35] .
Vestibular clinical/bedside tests
Vestibular clinical/bedside tests that were conducted are listed in Table 2 . During the Fukuda stepping test, subjects were asked to step or march 50 times with eyes closed and arms extended. A sideward rotation greater than 45 degrees were considered pathological. For the subjective visual vertical (SVV) test the the bucket method was used, described and illustrated elsewhere [36] , as bedside tool to detect abnormal subjective tilt.
The subjects looked into the bucket without having gravitational orientation clues and had to vertically straighten a line on the bottom inside of the bucket. The average of five repetitions was taken. Offsets greater than three degrees were considered pathological.
During the horizontal head impulse test the investigator stood in front of the subject and firmly held the head while rapidly rotating the head to both the left and right side by 20-30°.
The subjects had to maintain visual fixation and corrective eye movements; failure of visual fixation during these rapid head movements were considered pathological. Dynamic visual acuity testing was performed using a computerized VNG/ENG system (Micromedical Technologies Inc., Chatham, IL, USA). A visual optotype appeared when the head velocity exceeded 100 degrees per second and blanked during periods of low head velocity. The head was oscillated horizontally and vertically at a frequency of 2Hz.
Subjects had to identify the direction of the visual optotype correctly. Incorrect identification of the visual optotype that increased 2 or more times from baseline visual acuity during head rotation were considered pathological.
Next, the four channel Visual Eyes infrared video-based system (Micromedical Technologies Inc., Chatham, IL, USA) was used to record eye movements. The presence of spontaneous nystagmus was evaluated with and without fixation, and such presence was considered pathological. Subsequently, the subject's head was moved sinusoidally in the horizontal (yaw) plane at a cycle of 2Hz for 25-30 seconds and the presence of post headshake induced nystagmus was noted with vision denied. Post head shake nystagmus was considered pathological. Subjects were then asked to deeply inhale and exhale at a cycle of 1Hz for 45 seconds during which nystagmus induced by hyperventilation was noted with vision denied. The presence of nystagmus induced by hyperventilation was considered pathological.
Ocular motor tests
For the ocular motor tests the same infrared video goggles were used, during which eye movements were recorded. A digital light bar was used to perform the ocular motor tests.
Age and visual acuity may affect the outcomes of the ocular motor tests [37, 38] , therefore age was accounted for when selecting subjects, as well as their visual acuity. Gaze evoked nystagmus evaluated the subject's abilities to maintain gaze in eccentric positions, both horizontally and vertically. The presence of gaze evoked nystagmus was considered pathological. Random saccade testing was analysed according to the following parameters: velocity, latency and accuracy of the eye movements. Pursuit tracking was analysed for smooth eye movements, according to the following parameters: gain, symmetry and phase at the velocities of 0.1Hz, 0.2Hz and 0.4Hz. Any abnormalities in saccades and pursuit were considered pathological. Optokinetic testing was not performed because a full visual field stimulus was unavailable at the time.
Positioning/positional tests
Dix-Hallpike testing and various positional head and body nystagmus tests (also with vision denied) were performed using the infrared video goggles. The presence of nystagmus induced by position was considered pathological. 
Caloric irrigation
Identification of peripheral signs
The presence of at least one of the following findings suggested signs of a peripheral vestibular involvement: (i) spontaneous nystagmus inhibited by fixation and fixed direction;
( 
Identification of central signs
The or greater without a unilateral weakness.
Data analysis
All analyses of data were performed using the statistical software package SPSS for Windows version 21. Mean, standard deviation (±) and percentages were used to describe the data. One-way analysis of variance (ANOVA) was used to compare the distribution of HIV positive subjects between the three CDC categories. The One-Sample KolmogorovSmirnov Test was used to demonstrate normality of data. The independent samples t-test was used to compare mean values between the experimental and control groups. P values <0.05 were accepted as statistically significant. Effect sizes were determined using Cramer's V; and odds ratios were calculated. The chi-square non-parametric test was used to compare the findings between the two study groups and the three CDC categories.
Results
There was a significantly higher occurrence of vestibular involvement in subjects with HIV/AIDS (p=.001; chi-square). Peripheral and central vestibular involvement was measured in 79.2% of subjects with HIV compared to 18.4% of subjects without HIV ( n, number of subjects; %, percentage; SD, standard deviation; DP, directional preponderance. a = the mean unilateral weakness was calculated from 50 HIV positive subjects (1 subject excluded due to bilateral weakness, 2 due to hyperreflexia) and 37 HIV negative subjects (1 excluded due to bilateral weakness). b = subjects with an asymmetry ratio ≥40%. c = the mean asymmetry ratio was calculated from 44 HIV positive subjects (4 subjects excluded due to conductive and mixed hearing loss, 5 due to bilateral absent responses) and 37 HIV negative subjects (1 subject excluded due to bilateral absent responses). d = t-test for Equality of means (p<.05 was considered statistically significant). e = bilateral weakness or hypoactive response was regarded as total warm response from both sides less than 11 degrees per second and total cool response from both sides less than 6 degrees per second (56). f = hyperreflexia or hyperactive response was regarded as a total response more than 221 degrees per second g = chi-square (p<.05 was considered statistically significant).
Almost half (45.3%; n=24) of the HIV positive subjects with vestibular involvement had signs of peripheral vestibular involvement, while 22.6% (n=12) had peripheral with central vestibular involvement and 11.3% (n=6) had central vestibular involvement (Fig. 1) .
Among the subjects without HIV, only peripheral vestibular involvement occurred.
The types of vestibular test abnormalities presented by the groups are included in Table 2 .
Means were supplied for caloric and cVEMP tests due to the objective nature of the tests. Vestibular involvement was measured across all CDC categories of HIV (Fig. 2) .
Vestibular involvement was 18.9% in CDC category 1, 30.2% in category 2 and 30.1% in category 3. There were no statistically significant differences in the occurrence of vestibular involvement between category 1 and 2 (p=.65; chi-square) or between category 2 and 3 (p=.76; chi-square). Figure 2 illustrates that there were peripheral vestibular involvement and both peripheral and central involvement in category 1. Central signs (without peripheral signs) occurred in category 2 and category 3, and although there was a noticeable increase in its occurrence from earlier to more advanced stages of disease progression (3.8% to 7.5%), this was not statistically significant (p>.05; chi-square). In addition, the occurrence of peripheral with central vestibular involvement increased with disease progression as well, but this was also not statistically significant (p>.05; chisquare). Peripheral vestibular involvement increased from category 1 to category 2, but there was a slight decrease in its occurrence in category 3, which was not statistically significant (p=.43; chi-square). Vestibular symptoms which included dizziness, vertigo, disequilibrium and/or nausea and vomiting were reported by 37.7% of HIV positive subjects (n=20), while 62.3% (n=33) had no self-reported symptoms. In category 1, six subjects were symptomatic and nine were asymptomatic. In category 2, nine subjects were symptomatic and 11 were asymptomatic.
In category 3, five were symptomatic and 13 were asymptomatic. None of the HIV negative subjects reported having these symptoms. There was vestibular involvement in 35 .9% (n=19) of symptomatic HIV positive subjects compared to only one symptomatic subject (1.9%) who had normal vestibular function (p=.001; chi-square). In addition, there was a statistically significant (p=.05; chi-square) higher occurrence of vestibular involvement among asymptomatic HIV positive subjects (43.3%; n=23) compared to normal vestibular function in 20.7% (n=11) of asymptomatic subjects. Figure 3 compares the occurrence of vestibular involvement in HIV subjects with and without ARV therapies. There was no statistically significant difference between the occurrence of vestibular involvement in these two groups (p>.05; chi-square). 
Discussion
The current study demonstrated a significantly higher occurrence of vestibular involvement among adults with HIV than among those without HIV infections. There is a high likelihood of vestibular involvement in individuals with this disease, as demonstrated by the odds ratio. These findings correspond with previous studies that indicated a higher occurrence of vestibular dysfunction among adults with HIV [18, [24] [25] [26] 40] Vestibular involvement presented throughout all categories of HIV disease progression.
The occurrence of vestibular involvement increased from category 1 to category 2, but not from category 2 to category 3. Peripheral vestibular involvement decreased from 18.9% in category 2 to 11.3% in category 3. This was quite surprising, considering that three other studies showed a high occurrence of vestibular involvement in the advanced categories, particularly category 3 [17, 18, 26] . A possible suggestion for this equal occurrence in vestibular involvement in category 2 (30.2%) and category 3 (30.1%) and the decrease in peripheral vestibular involvement from category 2 to category 3 might be related to ARV therapies. In category 2, 38.2% of subjects with HIV used ARV therapies, while 40.5% of subjects in category 3 used ARV therapies. Administering ARV therapies and highly active antiretroviral therapy (HAART) has shown to prevent the progression of HIV [41] . A recent study [42] demonstrated no association between peripheral vestibular impairment among HIV positive subjects using HAART and HIV negative subjects. In this regard Cohen and colleagues [42] suggested a therapeutic effect on immunity. ARV therapies aim to restore immune function and help protect the body against secondary opportunistic infections that are associated with vestibular dysfunction. This, in turncan reduce the occurrence of peripheral vestibular dysfunction in advanced stages of the disease. Another possible explanation for the decrease in peripheral vestibular involvement in the advanced category, where the majority of subjects (n=13/18) were asymptomatic, might be that vestibular function was being compensated for centrally with increased disease duration.
However, the subjects with HIV did not know when they became infected with the virus and therefore the relationship between disease duration, disease category and compensated vestibular function is unclear. With such a multifactorial disease, a repeated measures within subjects design would have provided more conclusive evidence.
This study, together with two recent studies [17, 18] , showed that signs of central vestibular involvement increased throughout disease progression. These findings are in agreement with other studies [24, 40, 43] that demonstrated an association with centrally mediated ocular motor abnormalities, consistent with CNS dysfunction among HIV positive individuals. The occurrence of signs of central vestibular involvement in this study was smaller compared to those described by Teggi and colleagues [17, 18] . A possible explanation may be that the sample of subjects in this study consisted of both symptomatic and asymptomatic individuals and that almost two-thirds (62.3%) were asymptomatic. The studies by Teggi However, these diagnoses of opportunistic infections were not documented in any of the subjects' medical records when data was collected.
The significantly higher occurrence of peripheral vestibular involvement found in the subjects with HIV compared to those without HIV, could indicate that HIV affects the peripheral vestibular system directly. Abnormalities of the cVEMP suggested involvement of the saccule (otolith organ) and inferior vestibular nerve, while test procedures such as the head impulse, head shake, positional and caloric tests suggested involvement of the semi-circular canals and superior vestibular nerve. Several reports have indicated that HIV may directly affect the auditory system [49, 50] and because of the close anatomical proximity, shared nerve innervations and blood supply this may also affect the peripheral vestibular system. Mathews and colleagues [51] recently showed that HIV affects the auditory-vestibular pathway as demonstrated by the high incidence of sensorineural hearing loss and associated vestibular dysfunction in HIV positive compared to HIV negative subjects. However, the nature of this association in individuals with HIV is not yet clear. A post-mortem study [52] suggested that not only is the CNS vulnerable to direct viral infections, but the peripheral vestibular labyrinth neuroepithelium displayed a presence of viral-like particles that seemed characteristic of the human immune-deficiency virus. Specifically, pathologies were observed within the semi-circular canals as well as in both the otolith organs. Another report [53] [19, 56, 57] . cVEMP testing might therefore be considered useful in identifying peripheral vestibular involvement in individuals with HIV. Hausler and colleagues [26] found only central vestibular involvement in their sample of asymptomatic subjects, while peripheral vestibular involvement was reported only in the symptomatic subjects during the advanced stages of disease progression. In a study by Castello and colleagues [24] HIV infection seemed to have no effect on the vestibular labyrinth or eighth cranial nerve in the sample of asymptomatic subjects.
No other studies compared the occurrence of vestibular involvement in symptomatic and asymptomatic HIV positive subjects. The current findings therefore suggest that vestibular involvement, particularly peripheral vestibular involvement in HIV/AIDS, may be present, but sub-clinical in some patients Primary health care providers should be aware that patients with HIV have an increased prevalence of vestibular dysfunction. Once patients have symptoms, primary health care providers could consider referring them for vestibular assessments and vestibular rehabilitation therapy. Preventative measures could be taken to reduce the risk of serious, painful falls that can impede quality of life and activities of daily living. This may be especially important in light of recent evidence of a significant link between vestibular dysfunction and the risk of falling, even in asymptomatic subjects [58] .
The occurrence of vestibular involvement was equal in subjects receiving ARV therapies compared to those not receiving ARV therapies. This lack of differences was a surprising finding, considering a recent report [42] that demonstrated no significant difference in the prevalence of vestibular abnormalities in subjects with HIV using HAART and subjects without HIV. We therefore expected less vestibular abnormalities in HIV positive subjects using ARV therapies. The findings indicated that the administration of ARV therapies does not reduce the risk of having vestibular abnormalities. A possible explanation for dissimilar results of this study and that of Cohen and colleagues [42] , may be attributed to the vestibular test procedures employed. The current study employed a test battery consisting of various tests of peripheral and central vestibular function. It included objective measurements, such as caloric tests and cVEMP recordings. This might have made the study more sensitive for identifying vestibular disorders, even sub-clinical ones. The occurrence of vestibular test abnormalities despite the administration of ARV therapies, might be attributed to possible vestibulo-toxic properties. A detailed summary of reports on ototoxicity related to ARV can be found elsewhere [59] and some of the therapies included in this summary are, among others, Zidovudine (AZT), Didanosine (ddI), Stavudine (d4T), Lamivudine (3TC) and Nevirapine (NVP). The majority of these studies demonstrated that NRTIs were the most likely cause of the subjects' hearing loss. A recent study [60] indicated that their sample of HIV positive subjects who received ARV therapies showed more abnormalities in their auditory evoked potentials, such as auditory brainstem response, than those who did not receive ARV therapies. They suggested that the auditory nerve and brainstem structures were at-risk due to the ototoxic effect of these agents. This is a complex interaction, because it seems to result in ototoxicity for specific cases with specific ARV combinations, even involving interactions with other drugs, alongside possible person-specific susceptibility factors [59] . Reports on ototoxic ARV agents may suggest this as a possibility to explain the occurrence of vestibular involvement in HIV in earlier stages of the disease. ARV therapies improve general immunity avoiding secondary infections, therefore the improvement in the advanced stages may not just be due to ARV therapies but may include to central compensation. .
Conclusion
There is a high occurrence of vestibular involvement in adults with HIV. Primary health care providers could screen HIV positive patients to ascertain if there are symptoms of vestibular involvement. If there are any, then they may consider further vestibular assessments and subsequent vestibular rehabilitation therapy. HIV positive subjects have a high risk for vestibular abnormalities; these may occur despite being asymptomatic and/or receiving ARV therapies.
